HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $75

-2.46%

Structure Therapeutics, Inc.

GPCR

0.00

HC Wainwright & Co. analyst Andrew Fein maintains Structure Therapeutics (NASDAQ: GPCR) with a Buy and lowers the price target from $80 to $75.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

MiMedx Group (MDXG): Valuation in Focus After Promising EPIEFFECT Trial Results Spark Investor Interest

Breakthrough And Pullback | 4 Stocks Deserve Close Attention: BBIO, ROST And More

Wolfe Research Downgrades argenx to Peer Perform

HC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $51

Reported Earlier: YD Bio Through Its Partner 3D Global Biotech, Announces Exovisse Contact Lenses Has Obtained FDA 510(k) Clearance As A Class II Medical Device, Enabling Legal Marketing In The U.S.; Its Exovisse Artificial Tears Have Been Develop...

Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop

AlphaTON Capital Announces Plan To Acquire Telegram Bonds For Its Corporate Treasury

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up